GOALS OF WORK: Ginger has been used to treat numerous types of nausea and vomiting. Ginger has also been studied for its efficacy for acute chemotherapy-induced nausea and vomiting (CINV). However, its efficacy for delayed CINV in a diverse oncology population is unknown. MATERIALS AND METHODS: We performed a randomized, double-blind, placebo-controlled trial in 162 patients with cancer who were receiving chemotherapy and had experienced CINV during at least one previous round of chemotherapy. All participants were receiving a 5-HT3 receptor antagonists and/or aprepitant. Participants were randomized to receive either 1.0 g ginger, 2.0 g ginger daily, or matching placebo for 3 days. The primary outcome was change in the prevalence of delayed CINV. Secondary outcomes included acute prevalence of CINV, acute and delayed severity of CINV, and assessment of blinding. MAIN RESULTS: There were no differences between groups in the prevalence of delayed nausea or vomiting, prevalence of acute CINV, or severity of delayed vomiting or acute nausea and vomiting. Participants who took both ginger and aprepitant had more severe acute nausea than participants who took only aprepitant. Participants were able to accurately guess which treatment they had received. Ginger appeared well tolerated, with no difference in all adverse events (AEs) and significantly less fatigue and miscellaneous AEs in the ginger group. CONCLUSIONS: Ginger provides no additional benefit for reduction of the prevalence or severity of acute or delayed CINV when given with 5-HT3 receptor antagonists and/or aprepitant.
RCT Entities:
GOALS OF WORK: Ginger has been used to treat numerous types of nausea and vomiting. Ginger has also been studied for its efficacy for acute chemotherapy-induced nausea and vomiting (CINV). However, its efficacy for delayed CINV in a diverse oncology population is unknown. MATERIALS AND METHODS: We performed a randomized, double-blind, placebo-controlled trial in 162 patients with cancer who were receiving chemotherapy and had experienced CINV during at least one previous round of chemotherapy. All participants were receiving a 5-HT3 receptor antagonists and/or aprepitant. Participants were randomized to receive either 1.0 g ginger, 2.0 g ginger daily, or matching placebo for 3 days. The primary outcome was change in the prevalence of delayed CINV. Secondary outcomes included acute prevalence of CINV, acute and delayed severity of CINV, and assessment of blinding. MAIN RESULTS: There were no differences between groups in the prevalence of delayed nausea or vomiting, prevalence of acute CINV, or severity of delayed vomiting or acute nausea and vomiting. Participants who took both ginger and aprepitant had more severe acute nausea than participants who took only aprepitant. Participants were able to accurately guess which treatment they had received. Ginger appeared well tolerated, with no difference in all adverse events (AEs) and significantly less fatigue and miscellaneous AEs in the ginger group. CONCLUSIONS:Ginger provides no additional benefit for reduction of the prevalence or severity of acute or delayed CINV when given with 5-HT3 receptor antagonists and/or aprepitant.
Authors: Shivanand D Jolad; R Clark Lantz; Guan Jie Chen; Robert B Bates; Barbara N Timmermann Journal: Phytochemistry Date: 2005-07 Impact factor: 4.072
Authors: Q R Huang; M Iwamoto; S Aoki; N Tanaka; K Tajima; J Yamahara; Y Takaishi; M Yoshida; T Tomimatsu; Y Tamai Journal: Chem Pharm Bull (Tokyo) Date: 1991-02 Impact factor: 1.645
Authors: S Manusirivithaya; M Sripramote; S Tangjitgamol; C Sheanakul; S Leelahakorn; T Thavaramara; K Tangcharoenpanich Journal: Int J Gynecol Cancer Date: 2004 Nov-Dec Impact factor: 3.437
Authors: Julie L Ryan; Charles E Heckler; Joseph A Roscoe; Shaker R Dakhil; Jeffrey Kirshner; Patrick J Flynn; Jane T Hickok; Gary R Morrow Journal: Support Care Cancer Date: 2011-08-05 Impact factor: 3.603
Authors: Heather Greenlee; Lynda G Balneaves; Linda E Carlson; Misha Cohen; Gary Deng; Dawn Hershman; Matthew Mumber; Jane Perlmutter; Dugald Seely; Ananda Sen; Suzanna M Zick; Debu Tripathy Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: C C Hack; P Voiß; S Lange; A E Paul; S Conrad; G J Dobos; M W Beckmann; S Kümmel Journal: Geburtshilfe Frauenheilkd Date: 2015-07 Impact factor: 2.915